Denali治疗药品公司股票价格在价格目标降低后下跌,但分析师仍然认为它具有潜力。 Denali Therapeutics' stock price fell after a lower price target, but analysts still see potential.

Denali理疗公司股票价格在HC Wainwright降低价格目标后下跌, Denali Therapeutics' stock price dropped after HC Wainwright lowered its price target, though the firm still holds a "buy" rating. 该公司开发神经衰减和淋巴储存疾病的治疗方法,具有“机动购买”共识评级,平均目标价格为39.27美元。 The company, which develops treatments for neurodegenerative and lysosomal storage diseases, has a "Moderate Buy" consensus rating and an average target price of $39.27. 尽管最近内幕销售和机构所有权占92.92%,但分析家对股票的潜力基本保持乐观。 Despite recent insider selling and institutional ownership at 92.92%, analysts remain largely optimistic about the stock's potential.